Physician profile
Paul Perito
NPI 1851339824
$3,565,165.50
in general payments reported to CMS, 2019-2025
17 companies · $355K in 2025
The $355K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $794K · 2020: $343K · 2021: $567K · 2022: $596K · 2023: $471K · 2024: $439K · 2025: $355K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1.2M · Grant: $80K · Food and Beverage: $14K · Travel and Lodging: $3,519 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,164,175.00 |
| Grant | $80,000.00 |
| Food and Beverage | $14,199.96 |
| Travel and Lodging | $3,519.35 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,510.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $3,519,046.21 | 2019-2025 | Titan |
| Boston Scientific Corporation | $41,235.42 | 2019-2024 | |
| Rigicon,INC. | $4,455.09 | 2021-2023 | Rigi10 Malleable Penile Prosthesis |
| Endo Pharmaceuticals INC. | $59.84 | 2020-2022 | |
| Revance Therapeutics, INC. | $50.29 | 2024 | Daxxify |
| Acerus Pharmaceuticals Corporation | $44.89 | 2022 | |
| Urovant Sciences INC | $40.49 | 2021-2022 | |
| Astellas Pharma US INC | $38.75 | 2019 | |
| Teleflex LLC | $33.57 | 2022 | |
| Tolmar, INC. | $32.13 | 2024-2025 | Jatenzo |
| Baxter Healthcare | $31.26 | 2022 | |
| Endo USA, INC. | $21.86 | 2024 | Xiaflex |
| Kowa Pharmaceuticals America, INC. | $17.53 | 2023 | Seglentis |
| Metuchen Pharmaceuticals | $17.09 | 2019 | |
| Duchesnay USA Incorporated | $14.58 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amniox Medical, INC. | $14.43 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $12.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Perito listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.